Ascendis Pharma (ASND) Tops Q4 EPS by 37c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR1.54), EUR0.37 better than the analyst estimate of (EUR1.91). Revenue for the quarter came in at EUR137.7 million versus the consensus estimate of EUR85.87 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Investing.com’s stocks of the week
• Pathfinder Bancorp (PBHC) Tops Q2 EPS by 42c
• Home Federal Bancorp of Louisiana (HFBL) Tops Q2 EPS by 46c